The polymer pharmaceutical/drug characterization and processing facility

聚合物药物/药物表征和加工设施

• 批准号: LE0775684
• 负责人: Prof Andrew Whittaker
• 金额: $ 15.34万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Infrastructure, Equipment and Facilities
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LE0775684
• 关键词: polymer; pharmaceutical; drug; characterization; processing

The Australian population is ageing, and this is leading to ever increasing burdens upon our health system. In addition new understanding of disease states has lead to a demand for improved materials for drug delivery and for tissue regeneration. This proposal will lead to novel biomaterials designed to meet these demands. Polymers are seen as essential elements for construction of such biomedical devices due to the myriad forms in which they can be made, and the large number of different materials to choose from. This proposal will lead to the formation of the PolyPharma network which will produce polymeric biomaterials to benefit our health industries.

澳大利亚人口正在老龄化，这给我们的卫生系统带来了越来越大的负担。此外，对疾病状态的新理解已经导致对用于药物递送和用于组织再生的改进材料的需求。这一建议将导致新的生物材料设计，以满足这些需求。聚合物被视为构建这种生物医学设备的基本要素，因为它们可以制成无数种形式，并且有大量不同的材料可供选择。该提案将导致PolyPharma网络的形成，该网络将生产聚合物生物材料，以造福我们的健康产业。